Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Instagram Outage Disrupts Thousands of U.S. Users 
NEW YORK, Feb. 03, 2016 -- BeyondSpring Pharmaceuticals Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies including a Phase III immuno-oncology compound and a strong pipeline in collaboration with Fred Hutchinson Cancer Research Center, today announced that Lan Huang, PhD, Chairman and Chief Executive Officer, is scheduled to present at the 2016 BIO CEO & Investor Conference being held February 8-9, 2016 in New York City.
Dr. Huang is scheduled to present on Tuesday, February 9th 2016 at 2:00 PM EST. The presentation will take place at The Waldorf Astoria Hotel, Park North, Oncology Track.
Dr. Huang commented, “We are very excited to be presenting at the 18th Annual BIO CEO & Investor Conference. The event draws key constituents from the biotech community, including investors, analysts and company executives. We look forward to the opportunity to highlight BeyondSpring’s accomplishments and development plans for 2016.
BIO CEO & Investor Conference is focused on publicly traded as well as private biotech companies. It is an investor and networking conference dedicated to providing biotechnology and life sciences companies an opportunity to present to, and meet with, institutional investors, analysts and pharmaceutical executives. The event includes plenary sessions, educational sessions, company presentations, and one-on-one meetings.
BeyondSpring Pharmaceuticals’ management will also be available for one-on-one meetings at the conference. Registered participants interested in meeting with the Company may request a meeting using the BIO CEO one-on-one meeting portal.
About Plinabulin
BeyondSpring’s lead therapeutic candidate, Plinabulin, has begun a Phase III study to treat non-small-cell lung carcinoma (“NSCLC”). This 550-patient clinical trial is being conducted in the United States, China, and Australia. Evaluation and enrollment of patients in the U.S. has commenced, with additional sites to be added. The company recently announced that the China Food and Drug Administration (“CFDA”) has given a CTA (Clinical Trial Authorization) for the initiation of the China arm of the study.
Plinabulin has been evaluated in over 140 patients in the U.S. and select international locations. It has demonstrated promising anti-cancer activity in addition to a favorable safety profile. Plinabulin works via multiple mechanisms of action to alter the tumor microenvironment such as: 1) acting as an immuno-oncology agent to induce dendritic cell maturation and antigen specific T cell activation; 2) obliterating existing tumor vasculature by inhibiting tubulin polymerization and 3) activating the JNK pathway to induce tumor cell apoptosis. Plinabulin may be particularly effective against large tumors because of their more abundant tumor vasculature and greater tumor antigen. BeyondSpring is investigating additional clinical programs for Plinabulin in combination with PD-1/PD-L1 inhibitors and for other indications.
About BeyondSpring Pharmaceuticals
BeyondSpring Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring is focused on the advancement and commercialization of Plinabulin, a novel, Phase III cancer therapeutic initially targeting non-small-cell lung cancer.
Operationally, BeyondSpring utilizes a unique U.S.-China co-development platform to optimize clinical development speed while reducing costs. The Company has significant experience interacting with the FDA and CFDA. Thus, patient recruitment and clinical trials can be run simultaneously in both geographies, which offers the potential to substantially lower the cost of drug discovery/development and increase the speed of advancing novel therapies to clinical trials and, ultimately, to the market.
The Company has additional next-generation immuno-oncology assets, as well as a technology platform for targeted drugs and at least 6 new development compounds per year through a recently established 5 year research collaboration with the Fred Hutchinson Cancer Research Center.
Led by an expert management team consisting of pharmaceutical industry veterans from the U.S. and China, the Company is well positioned to further advance lead product candidate, Plinabulin, and its other programs. For more information, visit www.beyondspringpharma.com.
Contact: The Ruth Group Lee Roth (investors) [email protected] (646) 536-7012 Kirsten Thomas (media) [email protected] (508) 280-6592
